

# TABLE OF CONTENTS

## Book 9

Preface .....	i
Editorial Board .....	ii
Book 9 Panel .....	iii
Disclosure of Potential Conflicts of Interest .....	ix
Continuing Education and Program	
Evaluation Instructions .....	x
Book 9 Post Test .....	x
Role of ACCP .....	xv

## Gastroenterology I

### UPDATE ON PHARMACOTHERAPY OF CHRONIC HEPATITIS B AND C

Learning Objectives .....	1
Introduction .....	1
Hepatitis B Virus .....	1
Evaluation of Patients with Chronic HBV Infection .....	2
HBeAg-Positive Chronic HBV Infection .....	3
HBeAg-Negative Chronic HBV Infection .....	3
Pharmacologic Treatment Options for Chronic HBV Infection .....	4
Interferons for Chronic HBV Infection .....	5
Oral Nucleoside and Nucleotide Analogues for Chronic HBV Infection .....	6
Lamivudine .....	6
Adefovir Dipivoxil .....	6
Entecavir .....	6
Telbivudine .....	7
Tenofovir Disoproxil Fumarate .....	7
Combination Antiviral Therapy for Chronic HBV Infection .....	7
Antiviral Resistance .....	7
Management of Chronic HBV in Special Populations .....	8
HIV/HBV Coinfection .....	8
Pregnancy .....	8
Decompensated Cirrhosis .....	8
Liver Transplantation .....	9

Hepatitis B Reactivation .....	9
Hepatitis C Virus .....	10
Evaluation of Patients with Chronic HCV .....	10
Pharmacologic Treatment Options for HCV .....	10
Standard IFN-Based Therapy .....	12
Interferon alfacon-1 (Consensus IFN)-Based Therapy .....	12
Pegylated IFN-Based Therapy .....	12
Managing Adverse Effects of Chronic HCV Treatment .....	12
Management of Hematologic Adverse Effects .....	13
Management of Neuropsychiatric Adverse Effects .....	13
Treatment Challenges .....	14
African American Patients .....	14
HIV and HCV Coinfection .....	14
Treatment Nonresponse or Relapse .....	14
Liver Transplantation .....	14
Future Therapies for Chronic HCV Infection .....	15
Role of the Pharmacist .....	15
Conclusion .....	16
Annotated Bibliography .....	16
Self-Assessment Questions .....	21

### DRUG-INDUCED LIVER DISEASE

Learning Objectives .....	25
Introduction .....	25
Epidemiology .....	25
Risk Factors .....	25
Pathophysiology and Mechanisms of Drug-Induced Hepatotoxicity .....	26
Diagnosis .....	26
Assessment Instruments .....	27
Roussel Uclaf Causality Assessment Method .....	27
Clinical Diagnostic Scale .....	27
Drug-Induced Liver Injury Network .....	27
Classification of Drug-Induced Hepatotoxicity .....	27
Intrinsic Hepatotoxicity .....	27
Idiosyncratic Hepatotoxicity .....	28
Spectrum of Clinical Presentation .....	28
Acute Hepatocellular Hepatitis .....	28
Acute Cholestatic Hepatitis .....	28
Mixed Pattern Acute Hepatitis .....	28
Chronic Hepatitis .....	28
Vascular Injury .....	29
Other Forms of Less-Common Drug-Induced Liver Injury .....	29
Steatosis .....	29

Neoplastic Lesions .....	29
Granulomatous Hepatitis .....	29
Hepatotoxicity from Specific Drugs .....	29
Acetaminophen .....	29
Anesthetic Agents .....	30
Antimicrobial Agents .....	30
Antibacterial Drugs .....	30
Antituberculosis Drugs .....	31
Antifungal Drugs .....	31
Anticonvulsants .....	31
Phenytoin .....	31
Carbamazepine .....	31
Valproic Acid .....	32
Cardiovascular Agents .....	32
Antiarrhythmic Drugs .....	32
Antihypertensives .....	32
Anticoagulants .....	32
Warfarin .....	32
Heparins .....	33
Lipid-Lowering Agents .....	33
HIV Drugs .....	33
Nucleoside Reverse Transcriptase Inhibitors .....	33
Nonnucleoside Reverse Transcriptase Inhibitors .....	34
Protease Inhibitors .....	34
Hormonal Agents .....	34
Nonsteroidal Anti-inflammatory Drugs .....	34
Psychotropic Agents .....	35
Antidepressants .....	35
Antipsychotics .....	35
Dietary Supplements .....	35
Miscellaneous Drugs .....	36
Management of Drug-Induced Liver Disease .....	36
Role of the Pharmacist .....	37
Conclusion .....	37
Annotated Bibliography .....	37
<b>Self-Assessment Questions</b> .....	<b>41</b>

#### PEPTIC ULCER DISEASE: TREATMENT UPDATE

Learning Objectives .....	45
Overview of Peptic Ulcer Disease .....	45
Introduction .....	45
Epidemiology .....	45
<i>H. pylori</i> -Associated PUD .....	45
NSAID-Induced PUD .....	45
Pathophysiology .....	46
<i>H. pylori</i> -Associated PUD .....	46
NSAID-Induced PUD .....	47
Diagnosis of PUD .....	47
Clinical Signs and Symptoms .....	47
Diagnostic Tests for <i>H. pylori</i> .....	47
Drug Management and Prevention of PUD .....	48
NSAID-Induced PUD .....	48
Prevention of NSAID-Induced PUD .....	48
Drug Treatment of NSAID-Induced PUD .....	50
<i>H. pylori</i> -Associated PUD .....	50
Drug Treatment of <i>H. pylori</i> .....	50
ACG Guidelines .....	50
Clinically Relevant Issues Related to <i>H. pylori</i> Eradication Regimens .....	50
Management of Special Clinical Cases .....	52
Monitoring Therapy for PUD .....	52

Patient Education .....	53
Role of the Pharmacist .....	53
Conclusion .....	53
Annotated Bibliography .....	54
<b>Self-Assessment Questions</b> .....	<b>57</b>

## Gastroenterology II

### MANAGEMENT OF PATIENTS

#### RECEIVING BARIATRIC SURGERY

Learning Objectives .....	63
Introduction .....	63
Using Body Mass Index to Define and Classify Obesity .....	63
Prevalence of Overweight and Obesity .....	64
Current Treatment for Obesity .....	64
Indications, Treatment Goals, and Treatment Approaches .....	64
Lifestyle Modifications and Pharmacotherapy .....	65
Surgical Therapy .....	65
Evolution of Bariatric Surgery .....	65
General Principles and Historic Aspect .....	65
Contemporary Procedures .....	66
Roux-en-Y Gastric Bypass .....	66
Laparoscopic Adjustable Gastric Banding .....	68
Perioperative Management .....	69
Cardiac Management .....	69
Glycemic Management .....	69
Surgical Wound Infection .....	69
Thromboembolic Complications .....	69
Nutritional Management .....	70
Drug Management .....	70
Effects on Nutrient and Drug Absorption .....	71
Nutrient Absorption .....	71
Cobalamin, Folate, and Iron .....	71
Calcium and Vitamin D .....	72
Other Nutrients .....	73
Effect on Drug Absorption .....	73
Effect on Drug Metabolism and Transport .....	74
Role of the Pharmacist .....	74
Conclusion .....	75
Annotated Bibliography .....	75
<b>Self-Assessment Questions</b> .....	<b>79</b>

#### PROBIOTICS IN GASTROINTESTINAL DISEASE

Learning Objectives .....	83
Introduction .....	83
Overview of the Principles of Healthy Gastrointestinal Flora .....	83
History of Probiotic Use .....	83
Overview and Definition of Probiotics .....	84
Therapeutic Use of Probiotics .....	85
Antibiotic-Associated Diarrhea .....	85
Acute Gastroenteritis .....	85
Potential Benefits of Probiotic Therapy .....	86
Inflammatory Bowel Disease .....	86
Ulcerative Colitis .....	86
Pouchitis .....	87
Crohn's Disease .....	87
Irritable Bowel Syndrome .....	87
<i>Helicobacter pylori</i> .....	88

Complications of Probiotic Therapy .....	88
Role of the Pharmacist .....	89
Product Selection .....	89
Patient Education .....	91
Conclusion .....	91
Annotated Bibliography .....	92
<b>Self-Assessment Questions</b> .....	95

## COLON CANCER

Learning Objectives .....	99
Introduction .....	99
Epidemiology .....	99
Pathophysiology .....	100
Etiology and Risk Factors .....	100
Pathogenesis .....	100
Histologic Classification .....	101
Clinical Evaluation .....	101
Screening and Prevention .....	101
Presentation and Diagnosis .....	102
Staging .....	102
Prognosis .....	102
Treatment Options .....	103
Early Stage (Stage I) .....	103
Stage II .....	103
Fluorouracil and Leucovorin .....	103
Advanced Stage (Stage III) .....	105
Chemotherapy .....	105
Oxaliplatin .....	105
Capecitabine .....	105
Irinotecan .....	105
Metastatic Disease (Stage IV) .....	105
Chemotherapy .....	105
FOLFOX4 vs. FOLFIRI .....	105
Bevacizumab .....	105
Cetuximab .....	106
Panitumumab .....	106
The Role of the Pharmacist .....	107
Conclusion .....	107
Annotated Bibliography .....	107
<b>Self-Assessment Questions</b> .....	113

## Nutrition

### METABOLIC AND NUTRITION ISSUES IN PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY

Learning Objectives .....	119
Introduction .....	119
Continuous Renal Replacement Therapy .....	119
Acute Renal Failure and CRRT .....	119
Access for CRRT .....	119
Principles of CRRT .....	120
Continuous Renal Replacement Modalities .....	120
Slow Continuous Ultrafiltration .....	120
Continuous Hemofiltration .....	120
Continuous Hemodialysis .....	120
Continuous Hemodiafiltration .....	120
Nutritional Assessment in	
Patients Receiving CRRT .....	120
Anthropometrics .....	120
Bioelectrical Impedance Analysis .....	121

Laboratory Assessment .....	121
Nutrition Considerations in	
Patients Receiving CRRT .....	121
Metabolic Needs and Macronutrients .....	121
Energy Requirements .....	121
Dextrose .....	121
Lipids .....	121
Protein Requirements .....	121
Glutamine .....	122
Specialized Amino Acid Formulations .....	122
Fluids .....	122
Micronutrient Considerations .....	123
Electrolytes .....	123
Sodium .....	123
Potassium .....	123
Magnesium .....	123
Calcium .....	123
Phosphorus .....	124
Vitamins .....	124
Thiamine .....	124
Folic Acid .....	124
Vitamin C .....	124
Trace Elements .....	124
Selenium .....	124
Copper .....	124
Chromium .....	124
Zinc .....	124
Acid-Base Balance .....	125
Glycemic Control .....	125
Nutritional Intervention .....	125
Enteral Nutrition .....	125
Parenteral Nutrition .....	125
Monitoring Nutrition Support Therapy .....	126
Nitrogen Balance .....	126
Prealbumin .....	126
Triglycerides .....	126
The Role of the Pharmacist .....	126
Annotated Bibliography .....	126
<b>Self-Assessment Questions</b> .....	129

## HOME PARENTERAL NUTRITION

Learning Objectives .....	133
Introduction .....	133
Patient Selection .....	133
Indications .....	133
Home Assessment .....	134
Availability of Emergency Services .....	134
Discharge Planning .....	134
Setting Clinical and Nutritional Goals .....	134
Cost and Coverage for Home PN .....	135
Medicare .....	135
Medicaid .....	135
Private Insurance .....	135
Central Venous Access Devices .....	135
Tunneled CVADs .....	135
Implanted Ports .....	136
Peripherally Inserted Central Venous Catheters .....	136
Inappropriate CVADs for Home PN .....	136
Infusion Delivery Devices .....	136
Selecting an HCP .....	136
Patient Education .....	137
Starting PN in the Home .....	137

Complications of Home PN .....	137	Guidelines for Immunonutrition Use .....	158
Acute Complications .....	137	Pharmacist's Role .....	159
Dehydration .....	137	Conclusion .....	159
CVAD Malposition, Occlusion, and Thrombosis .....	138	Annotated Bibliography .....	159
CVAD-Related Infections.....	138	<b>Self-Assessment Questions</b> .....	163
Electrolyte Imbalances .....	138		
Sodium and Chloride .....	138	DIETARY SUPPLEMENTS	
Potassium, Magnesium, and Phosphorus .....	139	Learning Objectives .....	167
Calcium .....	139	Introduction .....	167
Acid-Base Abnormalities .....	139	Definitions .....	167
Blood Urea Nitrogen and Creatinine .....	139	Demographics of Dietary Supplement Use .....	167
Macronutrient Complications .....	139	Impetus for Dietary Supplement Use .....	167
Glucose .....	139	Regulatory and Legal Issues .....	168
Lipids .....	140	Dietary Supplement Health and Education Act of 1994 .....	168
Chronic Complications .....	140	Verification Programs and Industry Self-regulation .....	168
PN-Associated Liver Disease .....	140	Good Manufacturing Practices .....	168
Metabolic Bone Disease .....	140	Advertising .....	170
Small Intestine Bacterial Overgrowth .....	141	General Overview of Safety Issues .....	171
Vitamin Imbalances .....	141	Adverse Events and Dangerous Supplements .....	171
Anemia .....	141	Dietary Supplement Use in Special Populations .....	171
Zinc, Manganese, and Copper .....	142	Pediatrics .....	171
Additional Monitoring of Home PN Therapy .....	142	Pregnancy and Lactation .....	171
Weight .....	142	Geriatrics .....	171
Activities of Daily Living .....	143	Specific Dietary Supplements	
Laboratory and Other Tests .....	143	Subjected to Recent Clinical Trials .....	171
Adherence .....	143	Black Cohosh .....	171
Quality of Life .....	143	Ginkgo .....	172
Conclusion .....	143	Glucosamine .....	172
Annotated Bibliography.....	143	Green Tea .....	173
<b>Self-Assessment Questions</b> .....	147	Policosanol .....	174
		Saint John's Wort .....	174
IMMUNONUTRITION		Soy .....	175
Learning Objectives .....	151	Role of the Pharmacist .....	177
Introduction .....	151	Conclusion .....	177
Pathophysiology .....	151	Annotated Bibliography .....	177
Supplements and Mechanisms .....	151	<b>Self-Assessment Questions</b> .....	181
Glutamine .....	151		
Metabolism and Use .....	151		
Immune Effects .....	152		
Arginine .....	152		
Metabolism and Use .....	152		
Immune Effects .....	152		
Nucleotides .....	153		
Metabolism and Use .....	153		
Immune Effects .....	153		
Omega-3 Polyunsaturated Fatty Acids .....	153		
Metabolism and Use .....	153		
Immune Effects .....	153		
Antioxidant Vitamins/Minerals .....	153		
Therapeutic Goals/Outcomes .....	153		
Effect of Preexisting Nutritional Status .....	154		
Effect of Illness Severity .....	154		
Quality Patient Care .....	154		
Pharmacotherapy .....	154		
Treatment Plan .....	154		
Results in Critically Ill Patient Populations .....	154		
Trauma .....	154		
General and Oncologic Surgery .....	156		
Acute Respiratory Distress Syndrome/Acute Lung Injury .....	156		
Burns .....	157		
Mixed Critically Ill Populations .....	157		